



Contact:

Neothermia Corporation

Thomas M. Tully, President & CEO
508-655-7820

Rx Communications Group

Paula Schwartz (investors) 917-322-2216
Tony H. Loke (media) 917-322-2164

**NEOTHERMIA CORPORATION APPOINTS CHRISTOPHER A. BLECK
EXECUTIVE VICE PRESIDENT, MARKETING AND SALES**

NATICK, MA, January 18, 2005 -- Neothermia Corporation, an emerging leader in the development and marketing of minimally invasive systems for the diagnosis of cancer, announced today the appointment of Christopher A. Bleck to the newly created position of Executive Vice President, Marketing and Sales. Mr. Bleck will have responsibility for marketing, sales and customer service operations at Neothermia, reporting to President and Chief Executive Officer, Thomas M. Tully.

Mr. Bleck, 47, has more than 20 years of successful senior marketing and sales management experience in both the pharmaceutical and medical device industries. Most recently, he served as Vice President, Worldwide Marketing and Vice President, Commercial Operations, for Cytoc Corporation, a diagnostic and therapeutic medical device company focused on women’s health. In his positions at Cytoc, Mr. Bleck was responsible for a sales division of 200, and had full responsibility for the marketing and customer service teams. Prior to joining Cytoc, he spent 18 years in senior management at Abbott Laboratories, including positions as Corporate Vice President, Pediatric Products and President & General Manager, Abbott Canada. Mr. Bleck holds an M.B.A. and B.S. degree (in Pharmacy) from The University of Connecticut, located in Storrs, Connecticut.

“We are pleased to welcome Chris to the Neothermia team,” stated Mr. Tully. “Given his demonstrated abilities in marketing and sales management, Chris will play a pivotal role in further developing and integrating our sales and marketing strategies for the en bloc® breast biopsy system. With his guidance, we will be able to more effectively communicate the clinically-proven, superior diagnostic outcomes of the en bloc® to the nationwide breast care community and enhance our market penetration.”



About Neothermia Corporation

Founded in 1998, and based in Natick, Massachusetts, Neothermia is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the en-bloc[®] biopsy system, received approval from the Food and Drug Administration in June 2001. Initial products are targeted at breast biopsy and tumor excision.

For more information about Neothermia, please visit the Company's website at www.neothermia.com.

###